The Priority Review

Category

Regulation

Rules, guidance and how the agencies work.

68 stories ยท page 3 of 6

Stories

  1. FDA issues priority review voucher for EMCITATE (tiratricol)

    The FDA announced that EMCITATE (tiratricol), approved September 28, 2026, manufactured by Rare Thyroid Therapeutics International AB, meets the criteria for a priority review voucher. The tablet is indicated for treating peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 deficiency (Allan-Herndon-Dudley syndrome).

  2. FDA releases draft guidance on electronic IDE submission template

    Comments on the draft guidance are due by December 28, 2026. The guidance targets sponsors filing IDE applications with the Center for Devices and Radiological Health and the Center for Biologics Evaluation and Research.

  3. FDA releases draft guidance on U.S.-origin statements for seafood labeling

    The notice was published on October 27, 2026. It will provide examples of labeling statements that the FDA would consider truthful and not misleading once finalized.

  4. FDA determines PEPCID RPD famotidine tablets not withdrawn for safety or effectiveness

    The agency decided that the 20 mg and 40 mg orally disintegrating tablets were not removed from sale. This determination will allow FDA to approve abbreviated new drug applications for these products if all other legal and regulatory requirements are met.

  5. FDA actions, week of October 26, 2026: 2 approvals, 1 rule, 6 notices

    The FDA published 9 actions in the week of October 26 to November 1, 2026: 2 approval announcements, 1 final rule in the Federal Register and 6 notices in the Federal Register.

  6. FDA issues priority review voucher for ISEMBYLD (apitegromab-mstn)

    The FDA announced the issuance of a priority review voucher to the sponsor of ISEMBYLD (apitegromab-mstn), approved September 11, 2026. The voucher is awarded because the product meets the criteria for rare pediatric disease applications under the FD&C Act.

  7. AMA and EMA issue joint guidance on Ebola vaccine development

    The EMA's Emergency Task Force and the African Medicines Agency released a joint position paper outlining minimum requirements for clinical trials of Bundibugyo virus vaccines, including guidance on when animal toxicity studies may be waived. The paper also recommends early trials in Africa, a single-dose vaccine preference, and a ring trial design for Phase III studies.

  8. FDA corrects patent extension review periods for six drugs

    The FDA corrects the length of the regulatory review period for ANDEMBRY, ANZUPGO, ANKTIVA, BIZENGRI, BRINSUPRI, and DAYVIGO due to calculation errors. The corrections apply to determinations announced on August 10, August 17, and September 9, 2026; no other changes are made.

  9. FDA releases draft chapter on chemical hazard control for human food

    The FDA announced the availability of a new draft chapter, Chapter 12: Control of Chemical Hazards, as part of its multichapter draft guidance on Hazard Analysis and Risk-Based Preventive Controls for Human Food. The guidance is not final and is not yet in effect.

  10. FDA proposes action levels for cadmium in food for babies and young children

    The FDA announced a draft guidance titled "Action Levels for Cadmium in Processed Food Intended for Babies and Young Children" that will establish action levels for cadmium in certain processed foods intended for babies and young children less than 2 years old. The draft guidance is intended to set achievable action levels that will help further reduce cadmium in the food supply.

  11. FDA issues final guidance on prescription drug apps and software

    The FDA released final guidance on October 20, 2026 that clarifies when app content is subject to FDA submission requirements and when it should be mentioned on a drug's official label. The guidance identifies two categories of companion software-apps connected to a medical device and standalone apps-and sets conditions for labeling and what companies should submit to the agency.

  12. FDA actions, week of October 19, 2026: 5 approvals, 2 proposed rules, 2 notices, 1 announcement

    The FDA published 10 actions in the week of October 19 to 25, 2026: 5 approval announcements, 2 proposed rules in the Federal Register, 2 notices in the Federal Register and 1 press announcement.